Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | May 14, 2026 | May 15, 2026 |
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | CFO and Treasurer | January 31, 2017 | February 10, 2017 |
| Q32 Bio Inc.FIXX · Entity 5594 | See remarks | February 23, 2023 | February 27, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyra Therapeutics, Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Disposition to issuer · Disposed 640 · Balance 0 |
OCULAR THERAPEUTIX, INC
Report date January 31, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.56 · Expires 2027-01-30 | Direct | 90,000 |
Reported balance
After 2017-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-31 · Grant · Acquired 90,000 · Balance 90,000 F1: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.
Q32 Bio Inc.
Report date February 23, 2023 · Filed February 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-02-23 | Direct | 213,000 |
Reported balance
After 2023-02-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-23 · Grant · Acquired 213,000 · Balance 213,000 F1: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 36,000 |
Reported balance
After 2023-02-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-23 · Grant · Acquired 36,000 · Balance 36,000 F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.
F3: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 5, 2019 22:16 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 6,000 | $19.94 | $119,664.00 |
DisclosureSEC source: 0000899243-19-015653 · doc4.xml · nonDerivative · entry 2 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.46 to $20.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:16 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 6,000 | $0.64 | $3,840.00 |
DisclosureSEC source: 0000899243-19-015653 · doc4.xml · nonDerivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:20 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock option · Derivative | 88,000 | $0.00 Strike: $24.28 | $0.00 |
DisclosureSEC source: 0000899243-18-031340 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2028-12-14 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2019. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 22:47 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock option · Derivative | 49,711 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008914 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,711 Underlying: Common Stock · 49,711 shares Expires 2028-03-27 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following March 27, 2018. Read SEC document |
| January 31, 2017 Filed Feb 10, 2017 21:29 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000899243-17-003482 · doc4.xml · derivative · entry 1 Smith W Bradford · CIK 0001317678 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2027-01-30 F1 · derivative.exercise_date: Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.